COMMUNIQUÉS West-GlobeNewswire

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
04/05/2026
$55 million funded at closing to repay existing loan facility THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility [...]
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
04/05/2026
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome- [...]
Kyntra Bio to Report First Quarter 2026 Financial Results
04/05/2026
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on [...]
Option Care Health to Participate in the Bank of America Health Care Conference
04/05/2026
BANNOCKBURN, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
04/05/2026
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat data in [...]
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
04/05/2026
Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumors Two-trial strategy enables [...]
InspireMD Reports First Quarter 2026 Financial Results
04/05/2026
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for [...]
CooperCompanies Appoints Paul Keel to its Board of Directors
04/05/2026
SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director [...]
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
04/05/2026
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga [...]
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
04/05/2026
DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Teva to Present at the BofA Securities Health Care Conference
04/05/2026
PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical [...]
Jushi Holdings Inc. to Report First Quarter 2026 Financial Results on May 12, 2026
04/05/2026
BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) (OTCQX: JUSHF ) , a vertically integrated, multi-state cannabis operator, announced that it expects to [...]
REGIONAL HEALTH PROPERTIES ANNOUNCES APPOINTMENT OF MARLIE DAVIS AS CHIEF FINANCIAL OFFICER
04/05/2026
ATLANTA, GA, May 04, 2026 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (OTCQB: RHEP) today announced the appointment of Marlie Davis as Chief Financial Officer and retirement of Mark Stockslager from his role as [...]
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
04/05/2026
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
04/05/2026
Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and [...]
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
04/05/2026
RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
04/05/2026
ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflected continued [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/05/2026
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026
04/05/2026
NEW YORK, 04 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]

Pages